DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute myeloid leukemia who are ineligible for induction chemotherapy

BACKGROUND: Acute myeloid leukemia (AML) is predominantly a disease of older patients with a poor long-term survival. Approval of decitabine (DAC) in the European Union (EU) in 2012 for the treatment of patients with AML ≥65 years marks the potential for hypomethylating agents in elderly AML. Nevert...

Descripción completa

Detalles Bibliográficos
Autores principales: Grishina, Olga, Schmoor, Claudia, Döhner, Konstanze, Hackanson, Björn, Lubrich, Beate, May, Annette M., Cieslik, Caroline, Müller, Michael J., Lübbert, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4443550/
https://www.ncbi.nlm.nih.gov/pubmed/26008690
http://dx.doi.org/10.1186/s12885-015-1432-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4443550/
https://www.ncbi.nlm.nih.gov/pubmed/26008690
http://dx.doi.org/10.1186/s12885-015-1432-5

Ejemplares similares